The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia
Open accessAbstract
BACKGROUND: Cancer cachexia is a distressing weight loss syndrome commonly seen in advanced cancer patients. It is associated with reduced quality of life and shorter survival time. Eicosapentaenoic acid (EPA) is a long chain polyunsaturated fatty acid found naturally in some fish which has been used to decrease weight loss, promote weight gain and increase survival times in patients affected with cancer cachexia. OBJECTIVES: To evaluate the effectiveness and safety of EPA in relieving symptoms associated with the cachexia syndrome in patients with advanced cancer. SEARCH STRATEGY: Studies were sought through an extensive search of a range of electronic databases. Hand searching was conducted on selected journals and reference lists as well as contact made with investigators, manufacturers and experts. The most recent electronic search was conducted in February 2005. SELECTION CRITERIA: Studies were included in the review if they assessed oral EPA compared with placebo or control in randomised controlled trials of patients with advanced cancer and either a clinical diagnosis of cachexia or self-reported weight loss of 5% or more. DATA COLLECTION AND ANALYSIS: Both methodological quality evaluation of potential trials and data extraction were conducted by two independent review authors. MAIN RESULTS: Five trials (involving 587 patients) met the inclusion criteria. Three trials compared EPA at different doses with placebo with two outcomes, nutritional status and adverse events comparable across two of the three included trials. In addition, two trials compared different doses of EPA with an active matched control. It was possible to compare the outcomes of weight, quality of life and adverse events across these two trials. There were insufficient data to define the optimal dose of EPA. AUTHORS' CONCLUSIONS: There were insufficient data to establish whether oral EPA was better than placebo. Comparisons of EPA combined with a protein energy supplementation versus a protein energy supplementation (without EPA) in the presence of an appetite stimulant (Megestrol Acetate) provided no evidence that EPA improves symptoms associated with the cachexia syndrome often seen in patients with advanced cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Bioelectrical impedance analysis?part I: review of principles and methods
KYLE, U. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2004.06.004 · Cited by 3,200
Prognostic effect of weight loss prior tochemotherapy in cancer patients
Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., Cohen, M. H., Douglass, H. O., Engstrom, P. F., Ezdinli, E. Z., et al. (1980) · The American Journal of Medicine · doi:10.1016/s0149-2918(05)80001-3 · Cited by 2,354
Bioelectrical impedance analysis—part II: utilization in clinical practice
Kyle, U. G., Bosaeus, I., De Lorenzo, A. D., Deurenberg, P., Elia, M., Manuel Gómez, J., Lilienthal Heitmann, B., Kent-Smith, L., Melchior, J.-C., Pirlich, M., et al. (2004) · Clinical Nutrition · doi:10.1016/j.clnu.2004.09.012 · Cited by 2,350
Oxford Textbook of Palliative Medicine
(2009) · Oxford University Press eBooks · doi:10.1093/med/9780198570295.001.0001 · Cited by 1,920
Nutritional and metabolic assessment of the hospitalized patient
Blackburn, G. L., Bistrian, B. R., Maini, B. S., Schlamm, H. T., & Smith, M. F. (1977) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/014860717700100101 · Cited by 1,426
Fearon, K. C. H. (2003) · Gut · doi:10.1136/gut.52.10.1479 · Cited by 603
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
ESPEN practical guideline: Clinical Nutrition in cancer
Muscaritoli, M., Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Hütterer, E., Isenring, E., Kaasa, S., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.02.005 · Cited by 1,702
“2007, which concluded that there was insufficient evidence to support a recommendation for long-chain omega-3 fatty acids to treat cancer cachexia [51], two recent reviews demonstrate that long-chain fatty acids improved appetite, body weight, post-surgical morbidity, and quality of life in weight-losing cancer patien…”
BackgroundESPEN practical guideline: Clinical nutrition in surgery
Weimann, A., Braga, M., Carli, F., Higashiguchi, T., Hübner, M., Klek, S., Laviano, A., Ljungqvist, O., Lobo, D. N., Martindale, R. G., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.03.031 · Cited by 1,173
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Understanding the mechanisms and treatment options in cancer cachexia
Fearon, K., Arends, J., & Baracos, V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.209 · Cited by 940
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
Arends, J., Bodoky, G., Bozzetti, F., Fearon, K., Muscaritoli, M., Selga, G., van Bokhorst-de van der Schueren, M. A. E., von Meyenfeldt, M., Zürcher, G., Fietkau, R., et al. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.01.020 · Cited by 930
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
Arends, J., Strasser, F., Gonella, S., Solheim, T. S., Madeddu, C., Ravasco, P., Buonaccorso, L., de van der Schueren, M. A. E., Baldwin, C., Chasen, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100092 · Cited by 586
“However, when given to patients not receiving anticancer therapy, no benefit of N3P-ONSs was detected.(51)”
BackgroundESPEN Guidelines on Parenteral Nutrition: Non-surgical oncology
Bozzetti, F., Arends, J., Lundholm, K., Micklewright, A., Zurcher, G., & Muscaritoli, M. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2009.04.011 · Cited by 485
Cancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Multi-targeted therapy of cancer by omega-3 fatty acids
Berquin, I. M., Edwards, I. J., & Chen, Y. Q. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.044 · Cited by 364
Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer
Cockbain, A. J., Toogood, G. J., & Hull, M. A. (2012) · Gut · doi:10.1136/gut.2010.233718 · Cited by 305
S3-Leitlinie „Magenkarzinom” -
Moehler, M., Al-Batran, S.-E., Andus, T., Anthuber, M., Arends, J., Arnold, D., Aust, D., Baier, P., Baretton, G., Bernhardt, J., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0031-1273201 · Cited by 283
Cancer Cachexia: Mechanisms and Clinical Implications
Donohoe, C. L., Ryan, A. M., & Reynolds, J. V. (2011) · Gastroenterology Research and Practice · doi:10.1155/2011/601434 · Cited by 273
Nutritional screening and early treatment of malnutrition in cancer patients
Santarpia, L., Contaldo, F., & Pasanisi, F. (2011) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-011-0022-x · Cited by 267
Nutritional interventions for cancer-induced cachexia
Gullett, N. P., Mazurak, V. C., Hebbar, G., & Ziegler, T. R. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2011.01.001 · Cited by 114
DeFina, L. F., Marcoux, L. G., Devers, S. M., Cleaver, J. P., & Willis, B. L. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.002741 · Cited by 89
Soeters, P., Bozzetti, F., Cynober, L., Elia, M., Shenkin, A., & Sobotka, L. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2015.08.008 · Cited by 40
“It is unfortunate that different expert groups looking at the same literature material arrive at different conclusions and recommendations [56,57].”
Background
Metadata
- Authors
- Dewey, A., Baughan, C., Dean, T. P., Higgins, B., & Johnson, I.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2007-01-24
- Volume
- 2017
- Issue
- 12
- Pages
- CD004597-CD004597
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1908242390
- Cited by
- 257
- References
- 72
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.